| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Zinc finger and BTB domain-containing protein 22, Protein BING1, Zinc finger and BTB domain-containing protein 22A, Zinc finger protein 297, ZBTB22, BING1, ZBTB22A, ZNF297 |
| Entrez GeneID | 9278 |
| WB Predicted band size | 65.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This ZBTB22 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 476-502 amino acids from the C-terminal region of human ZBTB22. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ZBTB22抗体的3篇示例参考文献(注：以下内容为模拟示例，建议通过学术数据库验证真实性和获取完整文献)：
---
1. **文献名称**: *ZBTB22 regulates apoptosis in glioblastoma via transcriptional modulation*
**作者**: Smith A, et al.
**摘要**: 本研究利用ZBTB22抗体通过免疫印迹和免疫荧光技术，揭示了ZBTB22在胶质母细胞瘤细胞中的表达模式，并发现其通过调控促凋亡基因的转录影响肿瘤细胞存活。
---
2. **文献名称**: *ZBTB22 interacts with HIV-1 LTR and modulates viral latency*
**作者**: Chen L, et al.
**摘要**: 通过染色质免疫沉淀(ChIP)结合ZBTB22抗体，研究者发现ZBTB22与HIV-1长末端重复序列(LTR)结合，可能通过表观遗传修饰调控病毒潜伏期的维持。
---
3. **文献名称**: *Characterization of ZBTB22 antibody specificity in neurodegenerative disease models*
**作者**: Wang Y, et al.
**摘要**: 本研究验证了ZBTB22抗体的特异性，并发现ZBTB22在阿尔茨海默病模型中异常表达，提示其可能参与神经退行性变的分子通路。
---
**备注**：若需具体文献，建议在PubMed或Web of Science中以“ZBTB22 antibody”为关键词检索，并筛选涉及抗体实验(如Western blot、ChIP、IHC等)的研究。
The ZBTB22 antibody is a research tool designed to detect and study the ZBTB22 protein, a member of the zinc finger and BTB domain-containing (ZBTB) family. ZBTB22. also known as ZNF297 or FAZF, functions as a transcriptional regulator involved in diverse cellular processes, including cell differentiation, apoptosis, and immune response. Structurally, it contains a BTB domain for protein interactions and zinc finger motifs for DNA binding, enabling its role in gene expression modulation by recruiting chromatin-modifying complexes.
Research suggests ZBTB22 may play dual roles in cancer, acting as an oncogene or tumor suppressor depending on cellular context. It has been implicated in hepatocellular carcinoma, colorectal cancer, and hematological malignancies. Dysregulation of ZBTB22 is associated with altered cell proliferation and survival pathways. The antibody is widely used in techniques like Western blotting, immunoprecipitation, and immunohistochemistry to analyze its expression patterns, subcellular localization, and interactions with other proteins.
Recent studies highlight its potential involvement in DNA damage response and immune regulation, making it relevant for investigating therapeutic targets. Commercial ZBTB22 antibodies are typically validated for specificity across human and model organism samples. Continued research aims to clarify its mechanistic roles and clinical significance in disease pathogenesis.
×
